2-Methoxyanthraquinone

2-Methoxyanthraquinone

SCHEMBL222927

COc1ccc2c(c1)C(=O)c1ccccc1C2=O

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.60
MAPT P10636 5/20 0.57
TDP1 Q9NUW8 4/20 0.57
RAB9A P51151 4/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
NPC1 O15118 3/20 0.57
KDM4E B2RXH2 2/20 0.57
ALDH1A1 P00352 2/20 0.57
HPGD P15428 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
MAPK1 P28482 1/20 0.57
GAA P10253 1/20 0.57
ALOX12 P18054 1/20 0.57
TP53 P04637 2/20 0.56
POLB P06746 2/20 0.56
MAP2K7 O14733 1/20 0.56
GMNN O75496 1/20 0.56
LMNA P02545 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4645032 0.98 PTPN1 (0.58) PTPN1MAPTTDP1RAB9ASMN1; SMN2
SCHEMBL23111380 0.94 PTPRC (0.59) PTPN1MAPTTDP1RAB9ASMN1; SMN2
SCHEMBL17439396 0.94 MAPT (0.55) PTPN1MAPTTDP1RAB9ASMN1; SMN2
SCHEMBL2252533 0.94 CA1 (0.57) PTPN1MAPTRAB9AALDH1A1HPGD
SCHEMBL7451901 0.94 CA1 (0.57) PTPN1MAPTRAB9AALDH1A1HPGD
SCHEMBL2997273 0.90 PTPN1 (0.54) PTPN1MAPTTDP1RAB9ASMN1; SMN2
SCHEMBL10885799 0.89 CA1 (0.53) PTPN1MAPTRAB9AALDH1A1HPGD
SCHEMBL7786812 0.89 CA1 (0.57) PTPN1MAPTRAB9AALDH1A1HPGD
SCHEMBL30629120 0.89 CA1 (0.57) PTPN1MAPTTDP1RAB9ASMN1; SMN2
SCHEMBL8076766 0.89 CA1 (0.57) PTPN1MAPTTDP1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118420444-A Method for synthesizing benzaldehyde compound by immobilization and cooperative visible light catalysis 华中师范大学 2024-08-02 CN claimed
CN-118420445-A Method for synthesizing benzaldehyde compound by selective catalysis of visible light 华中师范大学 2024-08-02 CN claimed
EP-3943085-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2022-01-26 EP claimed
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH ZURICH (CH) 2021-06-24 US claimed
EP-3801507-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2021-04-14 EP claimed
US-3968131-A POLYOXYETHYLENE GLYCOL BASF AKTIENGESELLSCHAFT (DT) 1976-07-06 US claimed
CN-118420445-A Method for synthesizing benzaldehyde compound by selective catalysis of visible light 华中师范大学 2024-08-02 CN disclosed
CN-118420444-A Method for synthesizing benzaldehyde compound by immobilization and cooperative visible light catalysis 华中师范大学 2024-08-02 CN disclosed
US-20230159706-A1 FREE-RADICAL PHOTOINITIATORS AND USES OF SAME IN SILICONE COMPOSITIONS UNIVERSITE DE HAUTE ALSACE (FR) 2023-05-25 US disclosed
EP-3369780-B1 METHOD FOR MANUFACTURING SUBSTRATE AND METHOD FOR MANUFACTURING LIGHT EMITTING ELEMENT USING SAME TORAY INDUSTRIES (JP) 2022-10-26 EP disclosed
CN-111956636-B Application of 2-substituted anthraquinone derivative in preparation of medicines for treating candida albicans infection 中国药科大学 2022-03-18 CN disclosed
US-20220025130-A1 ISOLATION METHOD FOR WATER INSOLUBLE LIGNIN COMPONENTS OF A BIOMASS GREEN EXTRACTION TECHNOLOGIES 2022-01-27 US disclosed
EP-3943085-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2022-01-26 EP disclosed
US-4812489-A URETHANE ACRYLATE OLIGOMER, TRIS(2-HYDROXYETHYL)ISOCYANURATE TRIACRYLATE, REACTIVE DILUENT, AND A PHOTOPOLYMERIZATION INIATOR; CLADDING, BUFFER MATERIALS FOR OPTICAL FIBER UNITS THE YOKOHAMA RUBBER CO., LTD. (JP) 1989-03-14 US disclosed
EP-0284027-A2 Anaerobically curing adhesive sealing composition THREE BOND CO., LTD. (JP) 1988-09-28 EP disclosed
US-4739062-A REACTING AN AROMATIC COMPOUND WITH DICARBOXYLIC ACID COMPOUND USING METAL HALIDE CATALYST CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 1988-04-19 US disclosed
EP-0212329-A1 Process for the delignification of cellulosic materials INTEROX Société Anonyme (BE) 1987-03-04 EP disclosed
EP-0049221-B1 PROCESS FOR THE DELIGNIFICATION OF LIGNOCELLULOSIC MATERIAL CIBA-GEIGY AG (CH) 1983-12-21 EP disclosed
EP-0049221-A1 Process for the delignification of lignocellulosic material CIBA-GEIGY AG (CH) 1982-04-07 EP disclosed
US-3968131-A POLYOXYETHYLENE GLYCOL BASF AKTIENGESELLSCHAFT (DT) 1976-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION TOMM70, TOMM34, TIMM50 PTPN1 2166/4885MAPT 2071/4885TDP1 1658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.